BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - BioVie Inc. has announced a registered direct offering of 4,443,000 shares of its common stock at a price of $1.50 per share, aiming to raise approximately $6.66 million before expenses [1][2]. Group 1: Offering Details - The offering includes unregistered warrants for investors to purchase an equal number of shares at an exercise price of $1.37, exercisable six months post-issuance and expiring five years later [1][2]. - The expected closing date for the offering is around October 22, 2024, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be allocated for working capital and general corporate purposes [2]. Group 3: Company Overview - BioVie Inc. is focused on developing innovative drug therapies for chronic conditions, including neurological disorders like Alzheimer's and Parkinson's, as well as advanced liver disease [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in neurodegenerative diseases [5]. - BioVie’s orphan drug candidate BIV201 is under FDA Fast Track status and is being prepared for Phase 3 clinical testing to address liver cirrhosis complications [5].